Skip to content
Belantamab
Blenrep (belantamab) is an antibody pharmaceutical. Belantamab was first approved as Blenrep on 2020-08-25. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
blenrepBiologic Licensing Application2020-08-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple myelomaD009101C90.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01F: Monoclonal antibodies and antibody drug conjugates
L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
L01FX15: Belantamab mafodotin
HCPCS
Code
Description
J9037
Injection, belantamab mafodotin-blmf, 0.5 mg
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.022225337
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80333
Hematologic diseasesD006402EFO_0005803D75.9333
Blood protein disordersD001796333
Plasma cell neoplasmsD054219333
ParaproteinemiasD010265D47.2333
Corneal diseasesD003316H18.9333
Immunoglobulin light-chain amyloidosisD000075363122
Plasmablastic lymphomaD000069293C83.311
AmyloidosisD000686EFO_1001875E85111
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBELANTAMAB
INNbelantamab
Description
Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID2050232-20-5
RxCUI2387844
ChEMBL IDCHEMBL4298208
ChEBI ID
PubChem CID
DrugBankDB15719
UNII ID7M3UL8MR2Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TNFRSF17
TNFRSF17
Organism
Homo sapiens
Gene name
TNFRSF17
Gene synonyms
BCM, BCMA
NCBI Gene ID
Protein name
tumor necrosis factor receptor superfamily member 17
Protein synonyms
B cell maturation antigen, B-cell maturation factor, B-cell maturation protein, CD269
Uniprot ID
Mouse ortholog
Tnfrsf17 (21935)
tumor necrosis factor receptor superfamily member 17 (O88472)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 627 documents
View more details
Safety
Black-box Warning
Black-box warning for: Blenrep
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
947 adverse events reported
View more details